Robert William Ladner

US Patent:

7438890, Oct 21, 2008

Filed:

Jan 26, 2005

Appl. No.:

11/045477

Inventors:

Isaac J. Rondon - San Francisco CA, US
Robert Charles Ladner - Ijamsville MD, US

Assignee:

Dyax Corp. - Cambridge MA

International Classification:

A61K 38/00
A61K 38/04
A61K 38/08
A61K 38/10
A61K 38/12
A61K 49/00
A61K 51/08
C07K 4/00
C07K 7/00
C07K 7/04
C07K 9/00
C07K 11/00

US Classification:

424 169, 424 91, 424 934, 436 64, 514 2, 514 13, 514 14, 514 15

Abstract:

The present invention provides binding moieties for CEA, which have a variety of uses wherever detecting, isolating or localizing CEA, and particularly CEA as opposed to cross-reactive antigens such as NCA, is advantageous. Particularly disclosed are synthetic, isolated polypeptides capable of binding CEA, which is overexpressed in adenocarcinomas of endodermally derived digestive system epithelia and fetal colon. Such polypeptides and disclosed derivatives are useful, e. g. , as imaging agents for CEA-expressing tumors.

US Patent:

20110212467, Sep 1, 2011

Filed:

Aug 27, 2009

Appl. No.:

13/061068

Inventors:

Robert D. Ladner - Santa Monica CA, US
Nouri Neamati - Fullerton CA, US

Assignee:

UNIVERSITY OF SOUTHERN CALIFORNIA - Los Angeles CA

International Classification:

G01N 33/573
C12N 5/09
C07D 261/16
C07D 417/12
C07D 285/125
C07D 473/04

US Classification:

435 78, 435375, 548245, 548171, 548136, 544266

Abstract:

Evidence demonstrating that elevated expression of dUTPase protects breast cancer cells from the expansion of the intracellular uracil pool, translating to reduced growth inhibition following treatment with 5-FU is provided. The implementation of in silica drug development techniques to identify and develop small molecule inhibitors of dUTPase are reported. As 5-FU and the oral 5-FU pro-drug capecitabine remain central agents in the treatment of a variety of malignancies, the clinical utility of a small molecule inhibitor to dUTPase represents a viable strategy to improve the clinical efficacy of these mainstay chemotherapeutic agents.

US Patent:

20130029331, Jan 31, 2013

Filed:

Jun 14, 2012

Appl. No.:

13/523782

Inventors:

Peter M. Wilson - Pasadena CA, US
Robert D. Ladner - Santa Monica CA, US

Assignee:

UNIVERSITY OF SOUTHERN CALIFORNIA - Los Angeles CA

International Classification:

G01N 21/64
C07H 21/00

US Classification:

435 611, 536 231, 534727

Abstract:

The inventors have developed a rapid and sensitive fluorescence-based assay to quantify dNTPs. This assay relies on the principle that incorporation of a limiting dNTP is required for primer-extension and polymerase-mediated 5-3′ exonuclease hydrolysis of a quenched fluorophore-labeled probe resulting in fluorescence. The concentration of limiting dNTPs is directly proportional to the fluorescence generated. This assay has important applications in research that investigates the influence of pathological conditions or pharmacological agents on dNTP biosynthesis and regulation.